Purification of Monoclonal Antibodies for Human Clinical Use: Validation of DNA and Retroviral Clearance

  • Dave Brady
  • J. Bonnerjea
  • C. R. Hill

Abstract

The production of therapeutic grade monoclonal antibodies using mammalian cell culture requires the development of a purification process that consistently yields a safe and efficacious product. Process validation studies provide the assurance that the purification process is capable of reducing the levels of potential contaminants to safe and acceptable levels.

The monoclonal antibody purification process used at Celltech has been validated for its ability to remove DNA and retrovirus by means of challenge studies. Moloney Murine Leukaemia Virus and 32P-labelled murine hybridoma DNA were used to challenge individual chromatography steps that had been scaled-down to mimic the full-scale manufacturing process. These studies have demonstrated that the risk factors associated with contaminating DNA and virus can be substantially reduced by the purification procedure described here.

Keywords

Affinity Chromatography Purification Process Sodium Citrate Buffer Moloney Murine Leukaemia Virus Anion Exchange Column 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Kohler, G. and Milstein, C., Continuous culture of fused cells secreting antibody of predefined specificity.Nature (Lond.) 1975, 256. 495–497.CrossRefGoogle Scholar
  2. 2.
    Committee for Proprietary Medicinal Products. Guidelines on the production and quality control of monoclonal antibodies of murine origin intended for use in humans. Trends Biotechnol f 1988, 6, G5-G8.Google Scholar
  3. 3.
    Australian Department of Community Services and Health, Guidelines for the preparation and presentation of applications for general marketing of monoclonal antibodies intended for use in humans, G.P.O. Box 9848, Canberra, ACT 2601, Australia.Google Scholar
  4. 4.
    FDA Office of Biologies Research and Review, Points to consider in the manufacture and testing of monoclonal antibody products for human use, 1987, Bethesda, Maryland 20892, U.S.A.Google Scholar
  5. 5.
    Levy, J., Lee, H.M., Kawahata, R.T. and Spitler, L.E., Purification of monoclonal antibodies from ouse ascites eliminates contaminating mouse type C viruses and nucleic acids, Clin. Exp. Immunol. 1984, 56, 114–120.PubMedGoogle Scholar
  6. 6.
    Kenney, A.C., Large-scale purification of monoclonal antibodies. In Monoclonal Antibodies: Production and Application Alan R. Liss Inc., 1989, pp. 143-160Google Scholar
  7. 7.
    Ey, P.L., Prowse, S.J. and Jenkin, C.R. Isolation of pure IgG1 IgG2a and IgG2b immunoglobulins from mouse serum using protein A Sepharose, Immunochemistry, 1978, 15, 429.PubMedCrossRefGoogle Scholar

Copyright information

© SCI 1990

Authors and Affiliations

  • Dave Brady
    • 1
  • J. Bonnerjea
    • 1
  • C. R. Hill
    • 1
  1. 1.Celltech LtdSlough, BerksUK

Personalised recommendations